» 
OP Team steps up
Copy URL
https://www.pharmnovo.com/post/op-team-steps-up

OP Team steps up

September 5, 2022

PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.

In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.

Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.

Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.

Press release

LinkedIn

Petra Larson
Author:
Petra Larson
Copy URL
https://www.pharmnovo.com/post/op-team-steps-up

OP Team steps up

September 5, 2022

PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.

In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.

Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.

Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.

Press release

LinkedIn

Petra Larson
Author:
Petra Larson

Latest news

View all
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

A new perspective in pain management and opioid withdrawal relief

We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.

Read more
October 18, 2023

Phase IIa studies with WCT

Following the successful completion of our phase I study, we are pleased to announce our collaboration with WCT, Worldwide Clinical Trials, as the phase IIa study of our drug candidate PN6047. This partnership underscores our commitment to developing solutions for neuropathic pain. In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep. PN6047 offers a targeted approach to alleviate this condition, aiming to improve the overall pain experience. Insights on its efficacy will aid in designing subsequent phase IIb/III studies.

Read more
October 18, 2023

Meet Jesper Kjerulff, Chief operations officer and Global project lead

In the pharmaceutical development arena, experts like Jesper Kjerulff stand out. As Global project lead and Chief operations officer (COO) of PharmNovo, Jesper Kjerulff is instrumental in propelling the company's groundbreaking project, PN6047, and advancing the field of neuropathic pain management.

Read more